No connection

Search Results

MGRX vs QUCY

MGRX
Mangoceuticals, Inc.
BEARISH
Price
$0.39
Market Cap
$6.7M
Sector
Healthcare
AI Confidence
95%
QUCY
Mainz Biomed N.V.
BEARISH
Price
$0.49
Market Cap
$6.1M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
MGRX
--
QUCY
--
Forward P/E
MGRX
--
QUCY
--
P/B Ratio
MGRX
0.35
QUCY
7.38
P/S Ratio
MGRX
14.63
QUCY
11.35
EV/EBITDA
MGRX
-0.36
QUCY
-0.6

Profitability

Gross Margin
MGRX
54.91%
QUCY
72.58%
Operating Margin
MGRX
-1576.4%
QUCY
-2159.86%
Profit Margin
MGRX
0.0%
QUCY
0.0%
ROE
MGRX
-141.66%
QUCY
-488.32%
ROA
MGRX
-69.91%
QUCY
-89.61%

Growth

Revenue Growth
MGRX
-10.3%
QUCY
-32.9%
Earnings Growth
MGRX
--
QUCY
--

Financial Health

Debt/Equity
MGRX
0.02
QUCY
4.01
Current Ratio
MGRX
1.74
QUCY
0.5
Quick Ratio
MGRX
1.67
QUCY
0.27

Dividends

Dividend Yield
MGRX
--
QUCY
--
Payout Ratio
MGRX
0.0%
QUCY
0.0%

AI Verdict

MGRX BEARISH

MGRX exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -1576.40%. Despite a low Price-to-Book ratio of 0.35, the company is experiencing consistent revenue contraction (-10.30% YoY) and massive long-term value destruction, with a 5-year price decline of 99.3%. The lack of analyst coverage and bearish insider activity further signal a lack of confidence in the company's viability.

Strengths
Low Debt/Equity ratio (0.02)
Positive Gross Margin (54.91%)
Current Ratio of 1.74 suggests short-term liquidity
Risks
Extreme operating losses (-1576.40% operating margin)
Negative revenue growth both YoY and Q/Q
Severe long-term price decay (-99.3% over 5 years)
QUCY BEARISH

QUCY exhibits severe financial distress, anchored by a weak Piotroski F-Score of 3/9 and a critical liquidity crisis evidenced by a Current Ratio of 0.50. The company is suffering from catastrophic operational inefficiency with an operating margin of -2159.86% and a massive ROE of -488.32%. Despite beating negative earnings estimates, the fundamental trend is one of collapse, with revenue declining by 32.90% YoY and a 5-year price depreciation of 98.2%. The combination of high leverage (Debt/Equity 4.01) and shrinking revenues suggests a high risk of insolvency.

Strengths
Strong Gross Margin (72.58%) indicating product value
Recent trend of beating EPS estimates (3/4 quarters)
Positive Q/Q EPS growth (+38.5%) although still deeply negative
Risks
Severe liquidity risk with a Quick Ratio of 0.27
Extreme operational losses (Operating Margin -2159.86%)
Significant revenue contraction (-32.90% YoY)

Compare Another Pair

MGRX vs QUCY: Head-to-Head Comparison

This page compares Mangoceuticals, Inc. (MGRX) and Mainz Biomed N.V. (QUCY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile